Abstract
Epigenetic alterations like DNA methylation and the resulting inactivation of cancer-related genes often contribute to the development of various cancers. To identify the genes that are silenced by aberrant methylation in renal cell carcinoma (RCC), we subjected two RCC lines to methylated CpG island amplification/representational difference analysis. This identified 27 CpG islands. Combined bisulfite restriction analysis of these CpG islands in primary RCC cases revealed that four were methylated in a tumor-specific manner. One of these was identified as the human homeo-box gene B13 (HOXB13) gene, but the remaining three CpG islands were not associated with known genes. The methylation frequencies of HOXB13 in primary RCC samples and lines were 30 and 73%, respectively. The methylation status of HOXB13 correlated with the loss of its expression both in RCC lines and primary tumors, and methyltransferase inhibitor treatment induced the recovery of its expression. Exogenous expression of HOXB13 in RCC cells that lacked endogenous HOXB13 expression suppressed colony formation and induced apoptotic features. Furthermore, HOXB13 methylation correlated positively with tumor grade and microvessel invasion. These results suggest that HOXB13 is a novel candidate tumor suppressor gene in RCC and that its inactivation may play an important role in both RCC tumorigenesis and progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG . (2001). Hum Mol Genet 10: 687–692.
Clark SJ, Harrison J, Paul CL, Frommer M . (1994). Nucleic Acids Res 22: 2990–2997.
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X et al. (2000). Nat Genet 24: 132–138.
Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D et al. (2001). Proc Natl Acad Sci USA 98: 7504–7509.
Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ et al. (2004). Clin Cancer Res 10: 3972–3979.
Economides KD, Capecchi MR . (2003). Development 130: 2061–2069.
Economides KD, Zeltser L, Capecchi MR . (2003). Dev Biol 256: 317–330.
Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB et al. (2000). Cancer Res 60: 129–133.
Flagiello D, Poupon MF, Cillo C, Dutrillaux B, Malfoy B . (1996). FEBS Lett 380: 103–107.
Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA et al. (1994). Hum Mol Genet 3: 2169–2173.
Gardiner-Garden M, Frommer M . (1987). J Mol Biol 196: 261–282.
Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H et al. (1994). Nat Genet 7: 85–90.
Herman JG, Baylin SB . (2003). N Engl J Med 349: 2042–2054.
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S et al. (1994). Proc Natl Acad Sci USA 91: 9700–9704.
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP et al. (1998). Proc Natl Acad Sci USA 95: 6870–6875.
Herman JG, Jen J, Merlo A, Baylin SB . (1996). Cancer Res 56: 722–727.
Japanese Urological Association. The Japanese Society of Pathology. Japan Radiation Society (1999). General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma, 3rd edn. Kanehara Company: Tokyo.
Jones PA, Laird PW . (1999). Nat Genet 21: 163–167.
Jung C, Kim RS, Lee SJ, Wang C, Jeng MH . (2004a). Cancer Res 64: 3046–3051.
Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH . (2004b). Cancer Res 64: 9185–9192.
Katzenellenbogen RA, Baylin SB, Herman JG . (1999). Blood 93: 4347–4353.
Kikuchi T, Itoh F, Toyota M, Suzuki H, Yamamoto H, Fujita M et al. (2002). Int J Cancer 97: 272–277.
Mertens F, Johansson B, Höglund M, Mitelman F . (1997). Cancer Res 57: 2765–2780.
Morita R, Ishikawa J, Tsutsumi M, Hikiji K, Tsukada Y, Kamidono S et al. (1991). Cancer Res 51: 820–823.
Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D et al. (2001). Cancer Res 61: 7277–7281.
Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML et al. (2002). Cancer Cell 2: 157–164.
Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, Sonoda T et al. (2002). Clin Cancer Res 8: 3164–3171.
Okami J, Simeone DM, Logsdon CD . (2004). Cancer Res 64: 5338–5346.
Sato K, Tamura G, Tsuchiya T, Endoh Y, Usuba O, Kimura W et al. (2001). Br J Cancer 85: 199–203.
Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K et al. (2003). Cancer Res 63: 8606–8613.
Shuin T, Kondo K, Ashida S, Okuda H, Yoshida M, Kanno H et al. (1999). Contrib Nephrol 128: 1–10.
Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M et al. (1994). Cancer Res 54: 2852–2855.
Sreenath T, Orosz A, Fujita K, Bieberich CJ . (1999). Prostate 41: 203–207.
Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A et al. (2004). Clin Cancer Res 10: 2000–2006.
Thoenes W, Storkel S, Rumpelt HJ . (1986). Pathol Res Pract 181: 125–143.
Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T . (2004). Oncol Rep 12: 805–810.
Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D et al. (2002). Nat Genet 30: 406–410.
Toyota M, Issa JP . (1999). Semin Cancer Biol 9: 349–357.
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP . (1999a). Proc Natl Acad Sci USA 96: 8681–8686.
Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M et al. (1999b). Cancer Res 59: 2307–2312.
Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP . (1999c). Cancer Res 59: 4535–4541.
Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H et al. (2003). Proc Natl Acad Sci USA 100: 7818–7823.
Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, Issa JP et al. (2001). Cancer Res 61: 8540–8546.
Xiong Z, Laird PW . (1997). Nucleic Acids Res 25: 2532–2534.
Yoon JH, Dammann R, Pfeifer GP . (2001). Int J Cancer 94: 212–217.
Zeltser L, Desplan C, Heintz N . (1996). Development 122: 2475–2484.
Acknowledgements
This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Okuda, H., Toyota, M., Ishida, W. et al. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 25, 1733–1742 (2006). https://doi.org/10.1038/sj.onc.1209200
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209200
Keywords
This article is cited by
-
Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers
Clinical Epigenetics (2023)
-
Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in polish population
Hereditary Cancer in Clinical Practice (2022)
-
HOXA5 inhibits the proliferation of extrahepatic cholangiocarcinoma cells by enhancing MXD1 expression and activating the p53 pathway
Cell Death & Disease (2022)
-
HOXB13 expression is correlated with hepatic inflammatory activity of patients with hepatic fibrosis
Journal of Molecular Histology (2020)
-
miR-10b suppresses cell invasion and metastasis through targeting HOXA3 regulated by FAK/YAP signaling pathway in clear-cell renal cell carcinoma
BMC Nephrology (2019)